Home - AME Clinical Trials Review

Interviews with Outstanding Authors (2024)

In 2024, many authors shared their insights on clinical trials in our journal. Their articles published with us have received very well feedback in the field and stimulate a lot of discussions and new insights among the peers.

Hereby, we would like to highlight some of our outstanding authors who have been making immense efforts in their research fields, with a brief interview of their unique perspectives and insightful views as authors.

ACTR Annual Report 2024

Greetings from the Editorial Office of AME Clinical Trials Review (ACTR).

We are glad to present the 2024 Annual Report of ACTR, which has shown the author statistics, pageviews and visits of ACTR articles, as well as previews of upcoming reviews and commentaries in the coming year.

Prediction of lymphatic invasion for patients with early gastric cancer: a review

Elfriede Bollschweiler, Patrick S. Plum
Review Article｜25 August 2024
doi: 10.21037/actr-24-33

Advancing the understanding, reflection, and translation of clinical trials: inaugural editorial to AME Clinical Trials Review

I am excited to announce the launch of AME Clinical Trials Review (ACTR), an open-access, peer-reviewed journal publishing commentaries on clinical trials in all phases.

Why launch ACTR? Tens of thousands of clinical trials are published every year, and the total number of published clinical trials in PubMed is nearly a million, with an additional 80,000 recruiting and not-yet-recruiting studies registered in the ClinicalTrials.gov platform.

Cleaning the scope: have randomized clinical trials clarified the benefits of minimally invasive thoracic surgery for non-small cell lung cancer?—a narrative review

Eric M. Robinson, Raja Flores, Brian Housman
Review Article｜25 December 2024
doi: 10.21037/actr-24-149

‹ ›

Cover image "A Picture in a Picture" by Dr. Anthony P Yim, MD More >>

Articles in Press

Past Issues

About actr

Manuscript Submission

AME Editing Service

Reprint & Permission

Advertising

Contact us

General editorial enquiries:
Email: actr@amegroups.com
Copyright related contact:
Email: permissions@amegroups.com
Commercial Sales contact (Reprints, advertising, etc.):
Email: sales@amegroups.com

Editorial Commentary

Lessons from FOWARC: moving towards the more precise use of radiation therapy in the era of total neoadjuvant therapy

Aron Bercz, Wini Zambare, J. Joshua Smith

AME Clinical Trials Review

2025;

(25 April 2025)

PDF Full Text (58) Peer Review File COI Form Open Access

Editorial Commentary

Stereotactic ablative radiotherapy as a novel strategy in patients with oligometastatic hepatocellular carcinoma

Tomoki Kimura, Toshiki Fujiwara, Taro Ueda, Takuya Ogura, Shinji Kariya

AME Clinical Trials Review

2025;

(25 April 2025)

PDF Full Text (48) Peer Review File COI Form Open Access

Editorial Commentary

Finding the RIGHT Choice in patients with clinically aggressive ER-positive HER2-negative metastatic breast cancer

Maiane Maria Pauletto, Tomás Reinert

AME Clinical Trials Review

2025;

(25 April 2025)

PDF Full Text (42) Peer Review File COI Form Open Access

Editorial Commentary

Empowering treatment: insights from 35 months follow-up highlight the benefits of cemiplimab monotherapy and continued immunotherapy plus chemotherapy beyond progression in advanced non-small cell lung cancer patients with high PD-L1 expression

Maria Aguado Sorolla, Sergio Martínez-Recio, Andrés Barba Joaquin, Mikel Portu Grivé, Margarita Majem Tarruella

AME Clinical Trials Review

2025;

(25 April 2025)

PDF Full Text (50) Peer Review File COI Form Open Access

Editorial Commentary

Patritumab deruxtecan: advancing the treatment landscape for EGFR-resistant non-small cell lung cancer

Claudia Parisi, David Planchard, Fabrice Barlesi

AME Clinical Trials Review

2025;

(25 April 2025)

PDF Full Text (40) Peer Review File COI Form Open Access

Editorial Commentary

Emerging role of circulating tumor DNA as a predictive biomarker in consolidation immunotherapy for unresectable stage III NSCLC

Christian Huisman, Pim Rozendal, Ed Schuuring, T. Jeroen N. Hiltermann

AME Clinical Trials Review

2025;

(25 April 2025)

PDF Full Text (28) Peer Review File COI Form Open Access

Editorial Commentary

Revumenib: a new potential targeted therapy for KMT2A-rearranged acute leukemia

Xavier Thomas

AME Clinical Trials Review

2025;

(25 April 2025)

PDF Full Text (49) Peer Review File COI Form Open Access

Editorial Commentary

Intravascular imaging guided optimization in complex percutaneous coronary intervention (PCI)—does clinical presentation matter?

Vishal Goel, Nitesh Nerlekar, Adam J. Brown

AME Clinical Trials Review

2025;

(25 April 2025)

PDF Full Text (44) Peer Review File COI Form Open Access

Editorial Commentary

Is zilebesiran a novel effective and uniquely administered agent for an expanding therapeutic armamentarium for blood pressure control?

John M. Flack

AME Clinical Trials Review

2025;

(25 April 2025)

PDF Full Text (40) Peer Review File COI Form Open Access

Editorial Commentary

A SMART-er approach to upfront unresectable pancreatic adenocarcinoma

John Michael Bryant, Vaseem Khatri, Justyn Nakashima, Jessica Frakes, Sarah Hoffe

AME Clinical Trials Review

2025;

(25 April 2025)

PDF Full Text (39) Peer Review File COI Form Open Access

Editorial Commentary

Unpacking prostate-specific antigen dynamics and patient outcomes: insights from the ARASENS trial

Hayley Nicole Roberts, Corinne Maurice-Dror, Kim Nguyen Chi

AME Clinical Trials Review

2025;

(25 February 2025)

PDF Full Text (97) Peer Review File COI Form Open Access

Editorial Commentary

How do we improve chemoimmunotherapy in gastroesophageal adenocarcinoma?

Jane E. Rogers, Jaffer A. Ajani

AME Clinical Trials Review

2025;

(25 February 2025)

PDF Full Text (54) Peer Review File COI Form Open Access

Editorial Commentary

Final survival analysis from the LACC trial defines the current standard of care in surgical treatment of cervical cancer, however does not mark the final say

Sahar Salehi, Henrik Falconer

AME Clinical Trials Review

2025;

(25 February 2025)

PDF Full Text (282) Peer Review File COI Form Open Access

Editorial Commentary

Targeting menin in relapsed or refractory acute myeloid leukaemia—where the rubber hits the road

Wolfram C. M. Dempke, Klaus Fenchel

AME Clinical Trials Review

2025;

(25 February 2025)

PDF Full Text (106) Peer Review File COI Form Open Access

Editorial Commentary

Re-evaluating antiplatelet therapy post-coronary artery bypass grafting: insights from the DACAB trial’s five-year follow-up

Maria Comanici, Shahzad G. Raja

AME Clinical Trials Review

2025;

(25 February 2025)

PDF Full Text (62) Peer Review File COI Form Open Access

Editorial Commentary

Innovative dual approach: CD40 agonist and mFOLFIRINOX combination therapy in metastatic pancreatic cancer

Songul Kucukcelebi, Marjolein Y. V. Homs, Casper H. J. van Eijck

AME Clinical Trials Review

2025;

(25 February 2025)

PDF Full Text (61) Peer Review File COI Form Open Access

Editorial Commentary

DACAB trial supports long-term use of ticagrelor and aspirin dual therapy after coronary artery bypass grafting

Antoinette Cotton, Salil V. Deo

AME Clinical Trials Review

2025;

(25 February 2025)

PDF Full Text (59) Peer Review File COI Form Open Access

Editorial Commentary

Is EndoRotor the answer to residual colonic lesions?

Diego Cadena-Aguirre, Luciano Lenz, Fauze Maluf-Filho

AME Clinical Trials Review

2025;

(25 February 2025)

PDF Full Text (146) Peer Review File COI Form Open Access

Editorial Commentary

Should we target demethylation in acute myeloid leukemia?

Monia Marchetti

AME Clinical Trials Review

2025;

(25 February 2025)

PDF Full Text (59) Peer Review File COI Form Open Access

Editorial Commentary

Upfront axillary surgical management—a commentary on previously underrepresented patient groups and how the SENOMAC trial righted this wrong

Chelsea Marin, Kimberly R. Gergelis, Anna Weiss

AME Clinical Trials Review

2025;

(25 February 2025)

PDF Full Text (99) Peer Review File COI Form Open Access

View more articles

Currently no content available!

Editorial Commentary

What is the role of consolidation immunotherapy after chemoradiotherapy in stage III EGFR-mutant non-small cell lung cancer?

Toyoaki Hida

Published online: 20 October 2023

PDF Full Text (3117) Peer Review File COI Form Open Access

Editorial Commentary

The immune “tsunami” has arrived at the shores of early-stage non-small cell lung cancer

Antonio Rossi, Ettore Mari, Domenico Galetta

Published online: 06 September 2023

PDF Full Text (2859) Peer Review File COI Form Open Access

Editorial Commentary

Xaluritamig: a first step towards a new target, new mechanism for metastatic prostate cancer

Ruben Raychaudhuri, Michael T. Schweizer, Jessica E. Hawley, Lawrence Fong, Evan Y. Yu

Published online: 15 August 2024

PDF Full Text (2685) Peer Review File COI Form Open Access

Editorial Commentary

KEYNOTE-189 5-years update: setting a backbone for the next generation clinical research in advanced non-squamous non-small cell lung cancer without oncogenic addiction

Alessandra Merlini, Anis Cipi, Giorgia Ferrari, Paolo Bironzo

Published online: 11 June 2024

PDF Full Text (1799) Peer Review File COI Form Open Access

Editorial Commentary

The Butterfly effect—will the MARIPOSA-2 study alter the trajectory of EGFR mutated non-small cell lung cancer (NSCLC)

Yuji Uehara, Aaron C. Tan

Published online: 06 June 2024

PDF Full Text (1760) Peer Review File COI Form Open Access

Editorial Commentary

ADAURA: redefining the role of target therapy in resectable lung adenocarcinoma

Jairo A. Zuluaga, Leonardo Rojas, Oscar Arrieta, Andrés F. Cardona

Published online: 09 April 2024

PDF Full Text (1293) Peer Review File COI Form Open Access

Editorial Commentary

Induction therapy for acute myeloid leukemia: still nothing beyond 7+3?

Daniela Damiani, Mario Tiribelli

Published online: 20 June 2024

PDF Full Text (1144) Peer Review File COI Form Open Access

Editorial Commentary

Is osimertinib effective as 2nd line treatment in T790M-negative EGFR mutant NSCLC?

Panagiota Economopoulou, Ioannis Kotsantis, Amanda Psyrri

Published online: 09 April 2024

PDF Full Text (1044) Peer Review File COI Form Open Access

Editorial Commentary

Targeting TIGIT in lung cancer: will it stick to the wall?

Jiaxin Niu, Saba Radhi

Published online: 21 June 2024

PDF Full Text (1017) Peer Review File COI Form Open Access

Editorial Commentary

Intracranial efficacy of adagrasib in patients with KRAS G12C mutated non-small cell lung cancer (NSCLC): are results KRYSTAL clear?

Anuja Abhyankar, Grace K. Dy

Published online: 21 August 2024

PDF Full Text (907) Peer Review File COI Form Open Access

Editorial Commentary

Hyperthermic intraperitoneal chemotherapy in colorectal cancer: is COLOPEC just another brick in the wall?

Beate Rau, Sebastian Stintzing

Published online: 18 June 2024

PDF Full Text (908) Peer Review File COI Form Open Access

Editorial Commentary

Immunotherapy as first-line treatment in locally advanced/metastatic and previously untreated squamous cell lung cancer: which advances?

Noemi Maria Giorgiano, Francesca Pentimalli, Giovanni Natale, Carminia Maria Della Corte, Floriana Morgillo, Alfonso Fiorelli

Published online: 02 February 2024

PDF Full Text (934) Peer Review File COI Form Open Access

Editorial Commentary

The opening gambit: CheckMate 159 and the immunotherapy neoadjuvant era in non-small cell lung cancer

Igor Gómez-Randulfe, Raffaele Califano

Published online: 24 November 2023

PDF Full Text (953) Peer Review File COI Form Open Access

Editorial Commentary

EMPOWER Lung-3 Part 2: empowering options for anti-PD-1 and chemotherapy in non-small cell lung cancer with current landscape and remaining challenges

Mingjia Li, Dwight H. Owen, Gregory A. Otterson

Published online: 18 December 2023

PDF Full Text (888) Peer Review File COI Form Open Access

Editorial Commentary

Neoadjuvant osimertinib: a promising therapeutic option for locally advanced EGFR-mutant lung adenocarcinoma

Shinji Yuhara, Yoshihisa Shimada, Masaaki Sato

Published online: 27 March 2024

PDF Full Text (862) Peer Review File COI Form Open Access

Editorial Commentary

Utilization of pharmacokinetics in the dosing of pembrolizumab in non-small cell lung cancer

Lauren Tagliaferro Epler, Joel W. Neal

Published online: 29 January 2024

PDF Full Text (882) Peer Review File COI Form Open Access

Editorial Commentary

YK-029A in the landscape of treatments for non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations

Margaret Locke, Wint Yan Aung, Nagashree Seetharamu

Published online: 20 June 2024

PDF Full Text (825) Peer Review File COI Form Open Access

Editorial Commentary

The future of EGFR exon 20 targeting in non-small cell lung cancer

Petros Christopoulos

Published online: 13 June 2024

PDF Full Text (872) Peer Review File COI Form Open Access

Editorial Commentary

Is atezolizumab plus bevacizumab with chemotherapy effective for non-small cell lung cancer with EGFR- or ALK-alteration?

Yu Saida, Satoshi Watanabe, Toshiaki Kikuchi

Published online: 17 June 2024

PDF Full Text (829) Peer Review File COI Form Open Access

Editorial

Advancing the understanding, reflection, and translation of clinical trials: inaugural editorial to AME Clinical Trials Review

Kaiping Zhang

Published online: 31 May 2023

PDF Full Text (767) COI Form Open Access

Full Most Read article list >>

Journal Highlight more

AME Clinical Trials Review (AME Clin Trials Rev; ACTR) is an international, open-access, peer-reviewed online journal, publishing commentaries on all phases of clinical trials, including but not limited to the design, conduct, analysis, regulation and ethics. It is dedicated to sharing insights of the key opinion leaders to stimulate thought and discussion in clinical trials and facilitate the translation of the findings of clinical trials from bench to bedside, and to clinical practice. More >>